I'm not FOS. I'm reporting on what I learned today. Truth
I'm not FOS. I'm reporting on what I learned today. Truth or fiction - it's what I was told by someone who probably wasn't a Bioremedies 'exec'.
Furthermore - Doc's response to MikeyT (if it's legit) is typical and expected. He neither confirms nor denies anything ever. Of course BioRemediesMD doesn't speak for UNVC.
But today BioremediesMD spoke for BioremediesMD, and I am merely passing that on.
Here's what happened, for anyone who cares:
I called the BioRemediesMD phone number (as posted on Facebook). I dialed option #2 - 'support'. A younger sounding guy answered, at which point I referenced the 4 month old press release and asked him about a general time frame. He was specifically secretive, but I pressed him and was candid about the fact that I'm interested because I'm a UNVC investor. He said that things are still in the works and it was looking like another 3-6 months. He also confirmed it was still a project with Univec.
No secrets here, Folks!
I own 400k shares of this stock with you guys. Slapped the ask and bought another 20k today. I've never day-traded it. There's no flipping of $UNVC happening. Who's day-trading $UNVC right now? No one. It's only going down.
I've only ever asked legitimate questions here. I've never bashed anyone or shared anything that would indicate I'm playing two sides of the fence. I've only ever wanted our share price to go up.
So - why the continued animosity? Is this a contest? Or is this a message board for open communication?
Why are there always undertones of mistrust from certain longs here?
Use your heads, People. A guy can be wishy-washy about his hopes and thoughts. I can vascillate between doubtful and certain. But the bottom line is - I wouldn't invest so much time in any of my comments if I didn't care about this.
I've come full-circle on my opinions because of some dots I've connected in the past few days.
Furthermore, I've returned to posting positive messages with the hopes we might turn this board around and watch our PPS start going back up. Dare I say - attract new investors.
Everyone knows that right now - it's just the scared selling to the already hopeful.
This will be my last message on this board.
Good luck to everyone involved. I hope we all see those rainbows someday - whether sooner or later.
And to the guys in a competition for 'UNVC information king' - drop the egos. You're doing more harm than good at this point. There are too many of your peers who are teetering as I recently was.
So much for teamwork. I'm out.
5
3
Univec Conglomerate Inc (UNVC) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....
Continue Reading
An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...
Continue Reading
A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...
Continue Reading
Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...
Continue Reading
Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....
Continue Reading
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...
Continue Reading
Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...
Continue Reading
Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...
Continue Reading
Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...
Continue Reading
Top 5 Most Recently Viewed Articles
Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...
Continue Reading
Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...
Continue Reading
Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...
Continue Reading
Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...
Continue Reading
Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...
Continue Reading